United Therapeutics (UTHR) Rating Increased to Buy at Zacks Investment Research
United Therapeutics (NASDAQ:UTHR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday. The firm presently has a $160.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price objective indicates a potential upside of 13.26% from the stock’s previous close.
According to Zacks, “United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. The company, at present, has many phase III programs in the fields of cardiopulmonary diseases and oncology. It is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Several data read-outs and regulatory updates are expected in 2018. However, increased competitive pressure from Uptravi on its PAH drugs, mainly Orenitram, is a concern. We believe the company needs to use cash suitably to deal with generic competition for Remodulin that could materialize post Jun 2018. However, United Therapeutics’ shares have outperformed the industry in the past six months. Estimates have gone up ahead of the Q4 earnings release. The company has a mixed record of earnings surprises in the recent quarters. “
Several other research firms have also recently commented on UTHR. Oppenheimer raised their price target on shares of United Therapeutics to $180.00 and gave the stock an “outperform” rating in a report on Friday, January 5th. TheStreet cut shares of United Therapeutics from a “b-” rating to a “c” rating in a report on Friday, September 29th. Cowen restated a “hold” rating and set a $129.00 price target on shares of United Therapeutics in a report on Friday, October 27th. HC Wainwright restated a “hold” rating and set a $95.00 price target on shares of United Therapeutics in a report on Thursday, October 26th. Finally, Wedbush restated an “outperform” rating and set a $232.00 price target (up from $213.00) on shares of United Therapeutics in a report on Wednesday, December 27th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $140.45.
United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, topping the consensus estimate of $4.01 by $2.26. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The company had revenue of $445.50 million during the quarter, compared to analysts’ expectations of $426.43 million. During the same period last year, the company posted $4.23 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. equities research analysts expect that United Therapeutics will post 12.96 EPS for the current fiscal year.
In other news, Director Christopher Causey sold 580 shares of United Therapeutics stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $134.72, for a total value of $78,137.60. Following the transaction, the director now owns 1,555 shares of the company’s stock, valued at $209,489.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 1,241 shares of United Therapeutics stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $128.95, for a total transaction of $160,026.95. The disclosure for this sale can be found here. Insiders sold 15,773 shares of company stock valued at $1,925,637 over the last quarter. Corporate insiders own 7.80% of the company’s stock.
Several large investors have recently added to or reduced their stakes in UTHR. Quantbot Technologies LP raised its position in shares of United Therapeutics by 537.3% in the third quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 822 shares during the period. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of United Therapeutics in the third quarter valued at approximately $156,000. Toronto Dominion Bank raised its position in shares of United Therapeutics by 244.7% in the third quarter. Toronto Dominion Bank now owns 1,903 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 1,351 shares during the period. Meiji Yasuda Asset Management Co Ltd. bought a new position in shares of United Therapeutics in the third quarter valued at approximately $233,000. Finally, TLP Group LLC bought a new position in shares of United Therapeutics in the second quarter valued at approximately $246,000.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.